User profiles for Susan Zolla-Pazner
 | Susan B Zolla-PaznerProfessor of Medicine, Icahn School of Medicine at Mount Sinai Verified email at mssm.edu Cited by 31888 |
[HTML][HTML] Identifying epitopes of HIV-1 that induce protective antibodies
S Zolla-Pazner - Nature Reviews Immunology, 2004 - nature.com
During the past 20 years, the pendulum of opinion in the HIV-1 vaccine field has swung
between two extremes, initially favouring the induction of antibodies only, and subsequently …
between two extremes, initially favouring the induction of antibodies only, and subsequently …
[HTML][HTML] Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
<p>In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable
regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of …
regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of …
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)
…, D Mann, GD Sidhu, RE Stahl, S Zolla-Pazner… - Science, 1983 - science.org
Several isolates of a human type-C retrovirus belonging to one group, known as human T-cell
leukemia virus (HTLV), have previously been obtained from patients with adult T-cell …
leukemia virus (HTLV), have previously been obtained from patients with adult T-cell …
[HTML][HTML] Immune-correlates analysis of an HIV-1 vaccine efficacy trial
…, PB Gilbert, MJ McElrath, S Zolla-Pazner… - … England Journal of …, 2012 - Mass Medical Soc
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
[HTML][HTML] Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
S Zolla-Pazner, AC deCamp, T Cardozo… - PloS one, 2013 - journals.plos.org
The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox
(ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a …
(ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a …
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
…, G Stiegler, R Kunert, S Zolla-Pazner… - Journal of …, 2004 - Am Soc Microbiol
Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …
[PDF][PDF] Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies …
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies …
[HTML][HTML] Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
S Zolla-Pazner, T Cardozo - Nature reviews Immunology, 2010 - nature.com
One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune
responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine …
responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine …
Disseminated Kaposi's sarcoma in homosexual men
…, KSOO KIM, S ZOLLA-PAZNER - Annals of internal …, 1982 - acpjournals.org
Nineteen cases from an epidemic of disseminated Kaposi's sarcoma in homosexual men
were studied by clinical, virologic, immunologic, and genetic methods. The patients were all …
were studied by clinical, virologic, immunologic, and genetic methods. The patients were all …
[PDF][PDF] Robust and specific secretory IgA against SARS-CoV-2 detected in human milk
The SARS-CoV-2 immune response in human milk has not yet been examined, although
protecting infants and young children from COVID-19 is critical for limiting community …
protecting infants and young children from COVID-19 is critical for limiting community …
